NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: Implications for tumor growth retardation and docetaxel sensitivity

Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei

Dignam, J. D., Lebovitz, R. M., & Roeder, R. G. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.5.1475 · Cited by 11,262 · see citing works

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · see citing works

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · see citing works

Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine

Griffith, O. W. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90139-6 · Cited by 4,628 · see citing works

An Nrf2/Small Maf Heterodimer Mediates the Induction of Phase II Detoxifying Enzyme Genes through Antioxidant Response Elements

Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999 · see citing works

Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.

Carmichael, J., DeGraff, W., Gazdar, A. F., Minna, J. D., & Mitchell, J. B. (1987) · PubMed · Cited by 3,813 · see citing works

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798 · see citing works

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · see citing works

Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region

Moi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607 · see citing works

ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,593 · see citing works

Molecular Mechanisms Activating the Nrf2-Keap1 Pathway of Antioxidant Gene Regulation

Kobayashi, M., & Yamamoto, M. P. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.385 · Cited by 1,075 · see citing works

Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer

Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · see citing works

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996 · see citing works

Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers

Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986 · see citing works

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest

Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K. C.-Z., Lee, J.-H., Ciarallo, S., Catzavelos, C., Beniston, R., et al. (2002) · Nature Medicine · doi:10.1038/nm761 · Cited by 947 · see citing works

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · see citing works

NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer

Hayes, J. D., & McMahon, M. J. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 870 · see citing works

Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2

Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839 · see citing works

PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization

Shin, I., Yakes, F. M., Rojo, F., Shin, N.-Y., Bakin, A. V., Baselga, J. M., & Arteaga, C. L. (2002) · Nature Medicine · doi:10.1038/nm759 · Cited by 790 · see citing works

Molecular mechanisms of Nrf2‐mediated antioxidant response

Li, W., & Kong, A. T. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20465 · Cited by 786 · see citing works

Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer

Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · see citing works

Cancer related mutations in <i>NRF2</i> impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy

Shibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728 · see citing works

Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth

Ohta, T., Iijima, K., Miyamoto, M., Nakahara, I., Tanaka, H., Ohtsuji, M., Suzuki, T., Kobayashi, A., Yokota, J., Sakiyama, T., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5003 · Cited by 630 · see citing works

The ErbB receptors and their role in cancer progression

Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608 · see citing works

ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini

Muthuswamy, S. K., Li, D., Lelièvre, S. A., Bissell, M. J., & Brugge, J. S. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-785 · Cited by 554 · see citing works

Nrf2 signaling: An adaptive response pathway for protection against environmental toxic insults

Osburn, W. O., & Kensler, T. W. (2007) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2007.11.006 · Cited by 549 · see citing works

Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism

Tong, K. I., Kobayashi, A., Katsuoka, F., & Yamamoto, M. (2006) · Biological Chemistry · doi:10.1515/bc.2006.164 · Cited by 473 · see citing works

Genetic Alteration of Keap1 Confers Constitutive Nrf2 Activation and Resistance to Chemotherapy in Gallbladder Cancer

Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M. P., & Hirohashi, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.082 · Cited by 470 · see citing works

Different Electrostatic Potentials Define ETGE and DLG Motifs as Hinge and Latch in Oxidative Stress Response

Tong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. P. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-07 · Cited by 447 · see citing works

FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene

Zuo, T., Wang, L., Morris, Q., Chang, X., Zhang, H., Li, J. W., Liu, Y., Wang, Y., Liu, X., Chan, M. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.034 · Cited by 396 · see citing works

Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth

Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, G. S., & Biswal, S. S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0589 · Cited by 376 · see citing works

RNAi -Mediated Silencing of Nuclear Factor Erythroid-2–Related Factor 2 Gene Expression in Non–Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy

Singh, A., Boldin‐Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J. B., Blackford, A. L., Goodman, S. N., Bunz, F., Watson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1401 · Cited by 371 · see citing works

Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin

Kim, Y. R., Oh, J. E., Kim, M. S., Kang, M. R., Park, S. W., Han, J. Y., Eom, H., Yoo, N. J., & Lee, S. H. (2009) · The Journal of Pathology · doi:10.1002/path.2653 · Cited by 357 · see citing works

Role of Transcription Factor Nrf2 in the Induction of Hepatic Phase 2 and Antioxidative Enzymes in vivo by the Cancer Chemoprotective Agent, 3H-1, 2-Dithiole-3-thione

Kwak, M., Itoh, K., Yamamoto, M. P., Sutter, T. R., & Kensler, T. W. (2001) · Molecular Medicine · doi:10.1007/bf03401947 · Cited by 357 · see citing works

Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase

Yu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T. J., & Hung, M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80157-4 · Cited by 353 · see citing works

Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione.

Kwak, M.-K., Itoh, K., Yamamoto, M. P., Sutter, T. R., & Kensler, T. W. (2001) · PubMed Central · Cited by 330 · see citing works

Targeting NRF2 signaling for cancer chemoprevention

Kwak, M.-K., & Kensler, T. W. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.08.028 · Cited by 306 · see citing works

ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27 Kip1 -Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298 · see citing works

NRF2 Blockade Suppresses Colon Tumor Angiogenesis by Inhibiting Hypoxia-Induced Activation of HIF-1α

Kim, T., Hur, E.-G., Kang, S., Kim, J., Thapa, D., Lee, Y. M., Ku, S., Jung, Y., & Kwak, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3007 · Cited by 292 · see citing works

High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer

Jiang, T., Chen, N., Zhao, F., Wang, X.-J., Kong, B., Zheng, W., & Zhang, D. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0713 · Cited by 286 · see citing works

Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.

Yu, D., Liu, B., Tan, M., Li, J., Wang, S., & Hung, M. (1996) · PubMed · Cited by 220 · see citing works

A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity

Nioi, P., & Nguyen, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.051 · Cited by 212 · see citing works

Gain of Nrf2 Function in Non-Small-Cell Lung Cancer Cells Confers Radioresistance

Singh, A., Bodas, M., Wakabayashi, N., Bunz, F., & Biswal, S. S. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3219 · Cited by 210 · see citing works

Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.

Nimmanapalli, R., Perkins, C. L., Орландо, М., O'Bryan, E., Nguyen, D. N., & Bhalla, K. N. (2001) · PubMed · Cited by 202 · see citing works

p38 MAPK signalling cascades: ancient roles and new functions

Martı́n-Blanco, E. (2000) · BioEssays · doi:10.1002/1521-1878(200007)22:7 · Cited by 189 · see citing works

ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

Lenferink, A. E. G., Busse, D., Flanagan, W. M., Yakes, F. M., & Arteaga, C. L. (2001) · PubMed · Cited by 180 · see citing works

Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance

Cho, J., Manandhar, S., Lee, H., Park, H.-M., & Kwak, M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.10.022 · Cited by 167 · see citing works

Taxanes: an overview of the pharmacokinetics and pharmacodynamics

Vaishampayan, U. N., Parchment, R. E., Jasti, B., & Hussain, M. (1999) · Urology · doi:10.1016/s0090-4295(99)00451-3 · Cited by 145 · see citing works

Herceptin‐induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down‐regulation of ErbB2

Longva, K. E., Pedersen, N. M., Haslekås, C., Stang, E., & Madshus, I. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21015 · Cited by 142 · see citing works

Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway

Shim, G.-S., Manandhar, S., Shin, D., Kim, T., & Kwak, M. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.006 · Cited by 132 · see citing works

Global Downstream Pathway Analysis Reveals a Dependence of Oncogenic NF-E2–Related Factor 2 Mutation on the mTOR Growth Signaling Pathway

Shibata, T., Saito, S., Kokubu, A., Suzuki, T., Yamamoto, M. P., & Hirohashi, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0384 · Cited by 128 · see citing works

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

Yu, D., Liu, B., Jing, T., Sun, D., Price, J. E., Singletary, S. E., Ibrahim, N., Hortobágyi, G. N., & Hung, M. (1998) · Oncogene · doi:10.1038/sj.onc.1201729 · Cited by 127 · see citing works

Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27

Yang, H.-Y., Zhou, B. P., Hung, M., & Lee, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000147200 · Cited by 122 · see citing works

The Ets transcription factors of the PEA3 group: Transcriptional regulators in metastasis

de Launoit, Y., Baert, J., Chotteau‐Lelièvre, A., Monté, D., Coutte, L., Mauën, S., Firlej, V., Degerny, C., & Verreman, K. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.02.002 · Cited by 115 · see citing works

Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer

Yang, G. S., Thompson, J. A., Fang, B., & Liu, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206858 · Cited by 105 · see citing works

The combined immunodetection of AP-2α and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors

Allouche, A., Nolens, G., Tancredi, A., Delacroix, L., Mardaga, J., Fridman, V., Winkler, R., Boniver, J., Delvenne, P., & Begon, D. Y. (2008) · Breast Cancer Research · doi:10.1186/bcr1851 · Cited by 100 · see citing works

High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors

Rushworth, S. A., Bowles, K. M., & MacEwan, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3018 · Cited by 92 · see citing works

In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines

Merlin, J., Barberi‐Heyob, M., & Bachmann-Moisson, N. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf263 · Cited by 83 · see citing works

Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis

Geng, C.-X. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i4.696 · Cited by 70 · see citing works

Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel

Dong-xu, C., Qiao, B., Ge, Z., & Yuan, Y. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.03.047 · Cited by 46 · see citing works

Distal ERBB2 Promoter Fragment Displays Specific Transcriptional and Nuclear Binding Activities in ERBB2 Overexpressing Breast Cancer Cells

Delacroix, L., Begon, D., Chatel, G., Jackers, P., & Winkler, R. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.582 · Cited by 37 · see citing works

Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines

Bijman, M. N. A., van Berkel, M. P. A., Kok, M., Janmaat, M. L., & Boven, E. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832afc24 · Cited by 30 · see citing works

A new cis element is involved in the HER2 gene overexpression in human breast cancer cells.

Grooteclaes, M., Vernimmen, D., Plaza, S., Pasleau, F., Hodzic, D. M., & Winkler-Gol, R. (1999) · PubMed · Cited by 28 · see citing works

Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells

Manandhar, S., Lee, S., & Kwak, M. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-0511-z · Cited by 23 · see citing works

Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell

Choi, H. K., Yang, J. W., & Kang, K. W. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.005 · Cited by 18 · see citing works

Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease

Ngo, V., & Duennwald, M. L. (2022) · Antioxidants · doi:10.3390/antiox11122345 · Cited by 1,130 · see citing works

Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1

Na, H., & Surh, Y. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.10.819 · Cited by 202 · see citing works

Oncogenic functions of the transcription factor Nrf2

Gañán‐Gómez, I., Wei, Y., Yang, H., Boyano-Adánez, M. C., & Garcia‐Manero, G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.041 · Cited by 200 · see citing works

Potential Applications of NRF2 Inhibitors in Cancer Therapy

Panieri, E., & Saso, L. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8592348 · Cited by 185 · see citing works

Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – A comprehensive review from chemotherapy to immunotherapy

Kaboli, P. J., Salimian, F., Aghapour, S., Xiang, S., Zhao, Q., Li, M., Wu, X., Du, F., Zhao, Y., Shen, J., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104806 · Cited by 159 · see citing works

High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance

Ryoo, I.-G., Choi, B.-H., Ku, S., & Kwak, M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.04.015 · Cited by 149 · see citing works

Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance

Ryoo, I.-G., Lee, S.-H., & Kwak, M.-K. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2428153 · Cited by 133 · see citing works

Role of NRF2 in Ovarian Cancer

Tossetta, G., Fantone, S., Montanari, E., Marzioni, D., & Goteri, G. (2022) · Antioxidants · doi:10.3390/antiox11040663 · Cited by 123 · see citing works

Role of the Nrf2-heme oxygenase-1 pathway in silver nanoparticle-mediated cytotoxicity

Kang, S. J., Ryoo, I.-G., Lee, Y. J., & Kwak, M.-K. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.10.011 · Cited by 76 · see citing works

Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer

Wang, Y., Xie, H., Chang, X., Hu, W., Li, M., Li, Y., Liu, H., Cheng, H., Wang, S., Zhou, L., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3819 · Cited by 75 · see citing works

Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells

Ryoo, I.-G., Choi, B.-H., & Kwak, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3047 · Cited by 75 · see citing works

The Sensitivity of Cancer Cells to Pheophorbide a-Based Photodynamic Therapy Is Enhanced by NRF2 Silencing

Choi, B.-H., Ryoo, I.-G., Kang, H. C., & Kwak, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107158 · Cited by 67 · see citing works

HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction

Kang, H. J., Yi, Y. W., Hong, Y. B., Kim, H. J., Jang, Y., Seong, Y., & Bae, I. (2014) · Scientific Reports · doi:10.1038/srep07201 · Cited by 61 · see citing works

Targeting Nrf2 may reverse the drug resistance in ovarian cancer

Li, D., Hong, X., Zhao, F., Ci, X., & Zhang, S. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01822-1 · Cited by 60 · see citing works

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways

Yang, Y., Tian, Z., Guo, R., & Ren, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9867595 · Cited by 60 · see citing works

Deletion of Nrf2 impairs functional recovery, reduces clearance of myelin debris and decreases axonal remyelination after peripheral nerve injury

Zhang, L., Johnson, D. A., & Johnson, J. A. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.01.003 · Cited by 56 · see citing works

Expression of Pentose Phosphate Pathway-Related Proteins in Breast Cancer

Choi, J., Kim, E.-S., & Koo, J. S. (2018) · Disease Markers · doi:10.1155/2018/9369358 · Cited by 49 · see citing works

Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.

Liew, P., Hsu, C.-S., Liu, W.-M., Lee, Y., Lee, Y.-C., & Chen, C. (2015) · PubMed Central · Cited by 48 · see citing works

Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells

Panieri, E., & Saso, L. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8146 · Cited by 46 · see citing works

Oncogenes associated with drug resistance in ovarian cancer

Liu, X., Gao, Y., Lü, Y., Zhang, J., Li, L., & Yin, F. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1765-5 · Cited by 46 · see citing works

The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells

Tazehkand, A. P., Akbarzadeh, M., Velaie, K., Sadeghi, M. R., & Samadi, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.105 · Cited by 46 · see citing works

Nrf2 promotes progression of non-small cell lung cancer through activating autophagy

Wang, J., Liu, Z., Hu, T., Han, L., Yu, S., Yao, Y., Ruan, Z., Tian, T., Huang, T., Wang, M., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1312224 · Cited by 40 · see citing works

Shadows of NRF2 in cancer: Resistance to chemotherapy

Choi, B.-H., & Kwak, M. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.08.003 · Cited by 39 · see citing works

Differential Site-Based Expression of Pentose Phosphate Pathway-Related Proteins among Breast Cancer Metastases

Cha, Y. J., Jung, W. H., & Koo, J. S. (2017) · Disease Markers · doi:10.1155/2017/7062517 · Cited by 38 · see citing works

The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy

Chen, J., Solomides, C., Simpkins, F. A., & Simpkins, H. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3225-1 · Cited by 36 · see citing works

Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma

Cui, J., He, Y., Zhu, F., Gong, W., Zuo, R., Wang, Y., Luo, Y., Chen, L., Wang, C., Huo, G., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82980 · Cited by 34 · see citing works

Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer

LI, J., Zhang, Y., Gao, Y., Cui, Y., LIU, H., Li, M., & Tian, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3297 · Cited by 33 · see citing works

Apoptotic cell death induced by Z-Ligustilidein human ovarian cancer cells and role of NRF2

Lang, F., Qu, J., Yin, H., Li, L., Zhi, Y., Liu, Y., Fang, Z., & Hao, E. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.09.041 · Cited by 33 · see citing works

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

Khalil, H. S., Langdon, S. P., Goltsov, A., Soininen, T., Harrison, D. J., Bown, J., & Deeni, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12425 · Cited by 31 · see citing works

NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells

Choi, B.-H., Ryu, D. Y., Ryoo, I.-G., & Kwak, M. (2017) · Oncotarget · doi:10.18632/oncotarget.22513 · Cited by 31 · see citing works

NRF2 level is negatively correlated with TGF-β1-induced lung cancer motility and migration via NOX4-ROS signaling

Ryu, D.-Y., Lee, J., & Kwak, M. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01298-z · Cited by 26 · see citing works

Novel NRF2 ‐activated cancer treatments utilizing synthetic lethality

Baird, L., Kensler, T. W., & Yamamoto, M. P. (2022) · IUBMB Life · doi:10.1002/iub.2680 · Cited by 26 · see citing works

Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer

Yang, Y., Guo, R., Tian, X., Zhang, Z., Zhang, P., Li, C., & Feng, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.001 · Cited by 25 · see citing works

Suppression of Nrf2 confers chemosensitizing effect through enhanced oxidant-mediated mitochondrial dysfunction

Sompakdee, V., Prawan, A., Senggunprai, L., Kukongviriyapan, U., Samatiwat, P., Wandee, J., & Kukongviriyapan, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.112 · Cited by 23 · see citing works

The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions

Wang, J., Jin, Y., Cao, M., Zhao, Z., Cao, B., & Yu, S. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100028 · Cited by 20 · see citing works

Association of NRF2 Polymorphism with Cholangiocarcinoma Prognosis in Thai Patients

Khunluck, T., Kukongviriyapan, V., Puapairoj, A., Khuntikeo, N., Senggunprai, L., Zeekpudsa, P., & Prawan, A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.1.299 · Cited by 18 · see citing works

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies

Khalil, H. S., Langdon, S. P., Kankia, I. H., Bown, J., & Deeni, Y. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4148791 · Cited by 18 · see citing works

Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment

Zhou, Y., Wang, S., Guo, J., Li, C., Sui, M., Zeng, Z., Dang, H., Gu, Q., Zhu, J. Y., Cheng, Y., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.035 · Cited by 9 · see citing works

Intracellular Delivery of siRNAs Targeting AKT and ERBB2 Genes Enhances Chemosensitization of Breast Cancer Cells in a Culture and Animal Model

Fatemian, T., Moghimi, H. R., & Chowdhury, E. H. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090458 · Cited by 8 · see citing works

The Role of Genetic Polymorphisms in Nrf2 and P73 in Egyptian Women with Breast Cancer

Azhary, N. M. A., Kamel, M. M., Ismail, Y. M., Mahmoud, A., & Radwan, E. M. (2016) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2016.17.11.4945 · Cited by 8 · see citing works

Oxidative stress in the pathogenesis and prognosis of ovarian cancer

Pylväs-Eerola, M. (2015) · Cited by 3 · see citing works

NRF2 Drives Aggressiveness and Chemoresistance in Ovarian Cancer Stem-like Cells

Chang, Y., Wang, K., & Ding, D.-C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062820 · Cited by 2 · see citing works

The Potential Role of Nrf2-PD-L1 Axis in Promoting of Oxaliplatin Resistance in Colon Cancer CellsPreprint

Payandeh, Z., Tazehkand, A. P., Mansoori, B., Khaze, V., Asadi, M., Samadi, N., & Baradaran, B. (2020) · Research Square · doi:10.21203/rs.3.rs-58926/v1 · Cited by 2 · see citing works

NRF2 AND P73 POLYMORPHISMS IN EGYPTIAN WOMEN WITH BREAST CANCER

Hassan, I. A., Atia, H. A., El-Aziz, H. A. A., & Kamel, M. (2015) · Egyptian Journal of Biochemistry and Molecular Biology · doi:10.21608/ejb.2015.9838

Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer

Wang, Y., Xie, H., Chang, X., Hu, W., Li, M., Li, Y., Liu, H., Cheng, H., Wang, S., Zhou, L., et al. (2023) · doi:10.1158/0008-5472.c.6514289.v1

Abstract 1661: Knockdown of Nrf2 in cancer cells suppresses tumor growth: implication for the inhibitory role in HIF-1α and ErbB2 signaling

Kwak, M., Hur, E.-G., Kim, T., Manandhar, S., Choi, B.-H., & Ryu, I.-G. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-1661

Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells

Manandhar, S., Lee, S., & Kwak, M. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-0511-z · Cited by 23 · see citing works

Effect of Stable Inhibition of NRF2 on Doxorubicin Sensitivity in

Ovarian, H., Cells, C. O., Man, S., Lee, S., & Kwak, M.-K. (2009)

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib

Kankia, I. H., Khalil, H. S., Langdon, S., Moult, P., Bown, J., & Deeni, Y. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1864578 · Cited by 30 · see citing works

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors

Kankia, I. H., Poornima, P., Elcombe, M., Langdon, S. P., & Deeni, Y. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00040 · Cited by 1 · see citing works